Corcept's Profit Plunges 58% Despite Revenue Growth

Ticker: CORT · Form: 10-Q · Filed: Nov 4, 2025 · CIK: 1088856

Sentiment: bearish

Topics: Biopharmaceutical, Cushing's Syndrome, Operating Expenses, Net Income Decline, Revenue Growth, Stock Repurchases, R&D Spending

Related Tickers: CORT

TL;DR

**CORT's revenue growth is being eaten alive by massive spending hikes, making it a sell until they get costs under control.**

AI Summary

CORCEPT THERAPEUTICS INC (CORT) reported a significant decrease in net income for the three months ended September 30, 2025, falling to $19.668 million from $47.213 million in the prior year, a 58.3% decline. For the nine-month period, net income also decreased to $75.364 million from $110.463 million, a 31.8% drop. This decline occurred despite a robust increase in product revenue, which rose to $207.638 million for the quarter (up 13.7% from $182.546 million) and $559.282 million for the nine months (up 13.4% from $493.150 million). The primary driver for the reduced profitability was a substantial increase in operating expenses, particularly selling, general and administrative (SG&A) expenses, which surged by 68.1% to $123.977 million for the quarter and 61.7% to $318.488 million for the nine months. Research and development (R&D) expenses also increased by 16.0% to $68.846 million for the quarter. The company also significantly increased its common stock repurchases, spending $172.915 million in the nine months ended September 30, 2025, compared to $15.664 million in the same period of 2024.

Why It Matters

Corcept's latest 10-Q reveals a concerning trend for investors: while product revenue is growing, profitability is sharply declining due to soaring operating expenses, particularly in SG&A. This indicates potential competitive pressures or increased investment in market penetration for Korlym and its authorized generic, which could erode future margins. For employees, increased R&D spending might signal job stability in drug development, but the overall financial performance could impact compensation or future growth. Customers might benefit from increased marketing efforts, but the long-term sustainability of the company's financial health is crucial for continued product availability. The broader market will watch if this trend is specific to Corcept's niche in endocrinology or indicative of wider challenges in the biopharmaceutical sector.

Risk Assessment

Risk Level: high — The risk level is high due to a significant 58.3% decrease in net income for the quarter and a 31.8% decrease for the nine months, despite revenue growth. This is primarily driven by a 68.1% increase in selling, general and administrative expenses to $123.977 million for the quarter, indicating a substantial erosion of profitability and potential operational inefficiencies or aggressive spending that may not yield proportional returns.

Analyst Insight

Investors should closely scrutinize Corcept's operating expense management and demand clarity on the return on investment for the substantial increase in SG&A spending. Consider reducing exposure or holding off on new investments until there's clear evidence of expense control and a path back to stronger profitability, as current trends suggest significant margin compression.

Financial Highlights

revenue
$207,638,000
operating Margin
4.9%
total Assets
$823,607,000
net Income
$19,668,000
eps
$0.16
cash Position
$125,138,000
revenue Growth
+13.7%

Revenue Breakdown

SegmentRevenueGrowth
Product Revenue, Net$207,638,000+13.7%
Product Revenue, Net$559,282,000+13.4%

Key Numbers

Key Players & Entities

FAQ

Why did Corcept Therapeutics' net income decrease in Q3 2025 despite revenue growth?

Corcept Therapeutics' net income decreased to $19.668 million in Q3 2025 from $47.213 million in Q3 2024, a 58.3% drop, primarily due to a significant increase in operating expenses. Selling, general and administrative expenses surged by 68.1% to $123.977 million, and research and development expenses increased by 16.0% to $68.846 million.

What were Corcept Therapeutics' product revenues for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Corcept Therapeutics reported product revenue, net of $559.282 million. This represents a 13.4% increase compared to $493.150 million for the same period in 2024.

How much did Corcept Therapeutics spend on stock repurchases in the first nine months of 2025?

Corcept Therapeutics spent $172.915 million on repurchases of common stock in connection with its Stock Repurchase Program for the nine months ended September 30, 2025. This is a substantial increase from the $15.664 million spent in the same period of 2024.

What is Korlym and when was it approved by the FDA?

Korlym (mifepristone) 300 mg tablets is a once-daily oral medication developed by Corcept Therapeutics. It was approved by the United States Food and Drug Administration (FDA) in 2012 for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

What are the key changes in Corcept Therapeutics' balance sheet as of September 30, 2025?

As of September 30, 2025, Corcept Therapeutics' total assets decreased to $823.607 million from $840.553 million at December 31, 2024. Key changes include a decrease in cash and cash equivalents to $125.138 million from $127.665 million, and a significant increase in treasury stock to $(923.290) million from $(696.173) million.

What is Corcept Therapeutics' strategic outlook regarding new drug development?

Corcept Therapeutics is engaged in the discovery and development of medications by modulating the effects of the hormone cortisol. They have discovered and patented four structurally distinct series of selective cortisol modulators, consisting of more than 1,000 compounds, which they are developing as potential treatments for a broad range of serious disorders.

How did Corcept Therapeutics' cash flow from operating activities change in the first nine months of 2025?

Net cash provided by operating activities for Corcept Therapeutics decreased to $103.548 million for the nine months ended September 30, 2025, from $138.237 million in the same period of 2024. This decline occurred despite positive net income, influenced by changes in operating assets and liabilities such as trade receivables and inventory.

What is the impact of increased SG&A expenses on Corcept Therapeutics' profitability?

The substantial increase in selling, general and administrative (SG&A) expenses, which rose by 68.1% to $123.977 million for the three months ended September 30, 2025, significantly impacted Corcept Therapeutics' profitability. This surge in expenses outpaced revenue growth, leading to a 58.3% decrease in net income for the quarter and a 31.8% decrease for the nine-month period.

What accounting pronouncements has Corcept Therapeutics recently adopted or plans to adopt?

Corcept Therapeutics adopted ASU No. 2023-09 in December 2023, effective for the fiscal year ending December 31, 2025, which requires disaggregated information about effective tax rates and income taxes paid. They plan to adopt ASU No. 2024-03 for the fiscal year ending December 31, 2027, requiring additional expense category information, and ASU No. 2025-06 for the fiscal year ending December 31, 2028, which improves accounting for internal software.

What is Corcept Therapeutics' current inventory strategy?

Corcept Therapeutics holds significant quantities of active pharmaceutical ingredient (API) in raw materials and work in progress inventory. Inventory not expected to be utilized within 12 months of the balance sheet date, totaling $12.002 million as of September 30, 2025, is classified as 'strategic inventory' and presented as a non-current asset.

Risk Factors

Industry Context

Corcept Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on developing therapies for endocrine-related disorders. The industry is characterized by significant R&D investment, lengthy development cycles, and stringent regulatory oversight from bodies like the FDA. Success hinges on clinical trial outcomes, market access, and effective commercialization strategies.

Regulatory Implications

As a pharmaceutical company, Corcept is subject to extensive regulatory scrutiny regarding drug development, manufacturing, and marketing. Any adverse findings or changes in regulatory requirements could impact product approvals, market access, and overall financial performance. The company's significant R&D spending suggests ongoing efforts to navigate these regulatory pathways.

What Investors Should Do

  1. Monitor SG&A Expense Growth
  2. Analyze Share Repurchase Strategy
  3. Evaluate R&D Pipeline Progress
  4. Assess Operating Cash Flow Trends

Glossary

SG&A Expenses
Selling, General, and Administrative expenses represent the costs incurred in marketing, advertising, sales, and the overall management of a company. (A significant increase in SG&A expenses (68.1% in Q3 2025) was the primary driver for the decline in net income, despite revenue growth.)
Diluted Net Income Per Common Share
This metric represents the net income earned by a company for each share of its common stock outstanding, assuming all convertible securities (like stock options and convertible bonds) were exercised or converted. (Diluted EPS decreased significantly to $0.16 in Q3 2025 from $0.41 in Q3 2024, reflecting lower overall profitability.)
Common Stock Repurchases
When a company buys back its own shares from the open market, reducing the number of outstanding shares. (Corcept Therapeutics significantly increased its common stock repurchases in the first nine months of 2025, spending $172.9 million compared to $15.7 million in the prior year.)
Product Revenue, Net
The total revenue generated from the sale of the company's products after deducting any returns, allowances, and discounts. (Product revenue showed consistent growth, increasing by 13.7% in Q3 2025 and 13.4% for the nine-month period, indicating strong demand for its offerings.)
Income from Operations
This is the profit a company generates from its core business operations, calculated as revenue minus cost of goods sold and operating expenses. (Income from operations declined sharply from $46.598 million in Q3 2024 to $10.219 million in Q3 2025 due to the surge in operating expenses.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Corcept Therapeutics has demonstrated robust revenue growth, with net product revenue increasing by 13.7% in Q3 2025 and 13.4% for the nine months ended September 30, 2025. However, this top-line growth has been overshadowed by a significant surge in operating expenses, particularly SG&A, which rose by 68.1% in Q3 and 61.7% over nine months. This expense inflation has led to a sharp decline in net income and diluted EPS, with net income falling 58.3% in Q3 and 31.8% for the nine-month period. Additionally, the company has dramatically increased its share repurchase activity, indicating a shift in capital allocation strategy.

Filing Stats: 4,692 words · 19 min read · ~16 pages · Grade level 16.2 · Accepted 2025-11-04 16:12:58

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 3 CONDENSED CONSOLIDATED BALANCE SHEETS 3 CONDENSED CONSOLIDATED STATEMENTS OF INCOME 4 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 6 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY 8 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 10

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 18

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 25

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 25

OTHER INFORMATION

PART II. OTHER INFORMATION 26

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 26

RISK FACTORS

ITEM 1A. RISK FACTORS 27

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 42

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES 42

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 42

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 43

EXHIBITS

ITEM 6. EXHIBITS 44

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS CORCEPT THERAPEUTICS INCORPORATED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) September 30, 2025 December 31, 2024 (Unaudited) (See Note 1) ASSETS Current assets: Cash and cash equivalents $ 125,138 $ 127,665 Short-term marketable securities 296,545 255,669 Trade receivables, net of allowances 69,629 53,976 Inventory 12,349 12,412 Prepaid expenses and other current assets 37,469 21,880 Total current assets 541,130 471,602 Strategic inventory 12,002 3,583 Operating lease right-of-use asset 4,776 5,324 Property and equipment, net 2,094 2,689 Long-term marketable securities 102,557 219,831 Other assets 8,049 6,610 Deferred tax assets, net 152,999 130,914 Total assets $ 823,607 $ 840,553 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 34,446 $ 15,376 Accrued research and development expenses 28,322 33,868 Accrued and other liabilities 108,447 90,700 Short-term operating lease liability 1,050 829 Total current liabilities 172,265 140,773 Long-term operating lease liability 5,308 6,107 Long-term accrued income taxes payable 14,132 14,084 Total liabilities 191,705 160,964 Commitments and contingencies (Note 4) Stockholders' equity: Preferred stock — — Common stock 139 136 Treasury stock ( 923,290 ) ( 696,173 ) Additional paid-in capital 933,613 832,108 Accumulated other comprehensive income (loss) 2,341 ( 217 ) Retained earnings 619,099 543,735 Total stockholders' equity 631,902 679,589 Total liabilities and stockholders' equity $ 823,607 $ 840,553 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 CORCEPT THERAPEUTICS INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Product revenue, net $ 207,638 $ 182,546 $ 559,282 $ 493,150 Operating expenses: Cost of sales 4,596

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing